Clinical Report: Neurological Symptoms Associated with Wiskott–Aldrich Syndrome
Overview
Expand on age-dependent variations and case-fatality rates with specific examples.
Background
Wiskott–Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency characterized by microthrombocytopenia, eczema, and immunodeficiency. Neurological involvement in WAS has been underreported, primarily documented through isolated case reports, which limits understanding of its clinical implications. Recognizing neurological symptoms is crucial for improving patient outcomes and guiding treatment strategies.
Data Highlights
Category
Count
Median Age at Onset (years)
Case-Fatality Rate (%)
Brain Hemorrhagic
8
1.2
62.5
Immune-Mediated
6
3.8
0
Infectious
6
14.5
100
Neoplastic
12
5.0
75
Key Findings
The majority of individuals with WAS exhibiting neurological symptoms were pediatric (78.1%).
Neurological manifestations appeared a median of 3.0 years after WAS diagnosis.
Case-fatality rates varied significantly by phenotype: 100% in infectious, 75% in neoplastic, and 62.5% in hemorrhagic cases.
Infectious cases were predominantly associated with John Cunningham virus–positive progressive multifocal leukoencephalopathy.
Higher mortality rates were observed in non-transplant patients compared to those who underwent HSCT (63.6% vs 50.0%).
Clinical Implications
Clinicians should maintain a high index of suspicion for neurological symptoms in patients with WAS, particularly as they age. Early identification and management of neurological manifestations may improve outcomes and reduce mortality associated with severe complications.
Conclusion
The findings from this review emphasize the critical need for ongoing neurological surveillance in patients with Wiskott–Aldrich syndrome, particularly given the high case-fatality rates associated with certain neurological events.
